Current and emerging therapies for Addison's disease

@article{Napier2014CurrentAE,
  title={Current and emerging therapies for Addison's disease},
  author={Catherine M. Napier and Simon H S Pearce},
  journal={Current Opinion in Endocrinology \& Diabetes and Obesity},
  year={2014},
  volume={21},
  pages={147–153}
}
  • C. Napier, S. Pearce
  • Published 2014
  • Medicine
  • Current Opinion in Endocrinology & Diabetes and Obesity
Purpose of reviewThe purpose of this article is to review the current therapy of Addison's disease and to highlight recent developments in this field. Recent findingsConventional steroid replacement for Addison's disease consists of twice or three-times daily oral hydrocortisone and once-daily fludrocortisone; however, new treatment modalities such as modified-released hydrocortisone and continuous subcutaneous hydrocortisone infusion have recently been developed. These offer the potential for… Expand
Addison's disease and ACTH-producing pituitary microadenoma
TLDR
There is no relationship between Addison's disease and pituitary microadenoma, and the microadenomas is similar to Nelson's syndrome, the most satisfactory explanation of this patient's clinical picture. Expand
Adrenal crisis after first infusion of zoledronic acid: a case report
TLDR
Patients with Addison’s disease are at greater risk of having reduced bone mineral density and hip fractures and are thus more likely to receive a bisphosphonate than their peers and their usual oral dose of hydrocortisone should be doubled or even tripled. Expand
Adrenal insufficiency - recognition and management.
TLDR
Maintenance glucocorticoid -replacement is usually given as a twice or thrice daily hydrocortisone preparation, and regular monitoring for features of under- and over- replacement is essential during follow-up. Expand
Rethinking Pharmacological Nomenclature.
  • R. Seifert
  • Medicine
  • Trends in pharmacological sciences
  • 2018
TLDR
This opinion article is an attempt to generate discussion in the community that the better way forward to name/rename pharmacological terms would be according to their mechanism of action. Expand
Role of the X-linked gene GPR174 in autoimmune Addison's disease.
TLDR
A significant association of this X chromosome-encoded immunoreceptor with AAD for the first time is demonstrated, suggesting this X-linked gene could have a more generalized role in autoimmunity pathogenesis. Expand
A Pharmacokinetic Model of a Tissue Implantable Cortisol Sensor.
TLDR
A mathematical model is developed to predict dynamic cortisol concentrations in adipose, muscle, and brain tissues, where a significant number of important processes with cortisol occur, and can be used to inform the design of an implantable sensor. Expand
Pigmented Lesions of the Oral Mucosa
TLDR
This chapter provides a contemporary perspective of pigmented lesions of the oral mucosa and is intended to serve as a practical clinical resource for oral health-care providers. Expand
Physiologically Based Pharmacokinetics of Dexamethasone in Rats
TLDR
The physiologically based pharmacokinetic model describes the experimentally determined tissue and plasma dexamethasone (DEX) pharmacokinetics (PK) profiles in rats reasonably well and can serve for further investigation of DEX tissue distribution in rats as the PK driving force for PD effects in different tissues. Expand
Nuclear Receptor Function through Genomics: Lessons from the Glucocorticoid Receptor
TLDR
These genomic studies with the dual goals of advancing understanding of nuclear receptor-mediated transcription and stimulating thought on the development of anti-inflammatory and immunosuppressive ligands for GR that have reduced harmful effects on metabolism are highlighted. Expand
Molecular diversity of corticotropin-releasing hormone mRNA-containing neurons in the hypothalamus.
TLDR
It is suggested that CRH production reflects a state switch in hypothalamic neurons and thus confers functional competence rather than being an identity mark of phenotypically segregated neurons. Expand
...
1
2
...

References

SHOWING 1-10 OF 34 REFERENCES
Adrenal steroidogenesis after B lymphocyte depletion therapy in new-onset Addison's disease.
TLDR
New-onset autoimmune Addisons disease should be considered as a potentially reversible condition in some patients, and future studies of immunomodulation in autoimmune Addison's disease may be warranted. Expand
Residual adrenal function in autoimmune Addison's disease: improvement after tetracosactide (ACTH1-24) treatment.
TLDR
This is the first study to demonstrate that established autoimmune Addison's disease is amenable to a regenerative medicine therapy approach. Expand
Continuous subcutaneous hydrocortisone infusion in Addison's disease.
TLDR
A daily dose of approximately 10 mg/m(2) body surface area/day restores the circadian variation and normal levels of salivary cortisol in most patients, which is close to the estimated daily requirement. Expand
Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial.
TLDR
Positive effects on HRQoL were noted with CSHI, indicating that physiological glucocorticoid replacement therapy may be beneficial and that CSHI might become a treatment option for patients poorly controlled on conventional therapy. Expand
Long-lasting subclinical Addison's disease.
TLDR
Autoimmune adrenal disease can have a very long preclinical period even with high concomitant ACTH and specific antibody titers. Expand
Partial recovery of adrenal function in a patient with autoimmune Addison’s disease
TLDR
If the patient with primary adrenal insufficiency caused by autoimmune adrenalitis is not unique this could have profound effects on treatment and follow-up of Addison’s disease. Expand
Spontaneously resolving Addison's disease.
TLDR
A case of a patient with Addison's disease who has had a spontaneous recovery is reported, generally regarded as an irreversible, progressive disease. Expand
Adrenal crisis in treated Addison's disease: a predictable but under-managed event.
TLDR
The endocrinologist has a responsibility to ensure that Addison's patients have adequate access to life-saving emergency injection materials and repeated, practical training sessions in how to use them, while the general practitioner plays a vital role as in arranging prompt emergency admissions. Expand
Consensus statement on the diagnosis, treatment and follow‐up of patients with primary adrenal insufficiency
TLDR
A European Expert Consensus Statement for diagnosis, treatment and follow‐up ofPrimary adrenal insufficiency is attempted to provide a guide for the treatment and detection of new autoimmune diseases. Expand
Premature mortality in patients with Addison's disease: a population-based study.
TLDR
It is observed that the risk ratio for death was more than 2-fold higher in patients with Addison's disease compared with the background population, and cardiovascular, malignant, and infectious diseases were responsible for the higher mortality rate. Expand
...
1
2
3
4
...